SPHERE: NHMRC Centre of Research Excellence in Sexual and Reproductive Health for Women in Primary Care, October 2022 The primary objective of the webinar is to provide general practitioners, practice nurses and community pharmacists with the support required to initiate EMA services in their area. This will be undertaken by providing an overview of: • the context of South Australian legislation...
NAPWHA, ASHM, AFAO, May 2022 From 1st July, people with HIV who are ineligible for Medicare, and who previously received HIV medication through compassionate access schemes, will be required to transition to alternative access arrangements in order to receive government-funded treatment*. Option 1: individuals will need to engage in care with a public hospital-based physician and have their...
Changes in use of hormonal long‐acting reversible contraceptive methods in Australia between 2006 and 2018: A population‐based study Luke E. Grzeskowiak, Helen Calabretto, Natalie Amos, Danielle Mazza, Jenni Ilomaki ANZJOG First published: 23 October 2020, Abstract: Background Long‐acting reversible contraceptives (LARCs) are promoted internationally as a key strategy for reducing unintended...
Alcohol and Drug Foundation (Australia), April 27th 2020 There are now new challenges for people who access opioid replacement therapy (ORT) due to the COVID-19 (coronavirus) pandemic. Many may be experiencing anxiety and fear due to COVID-19 and trying to reduce and mitigate these feelings is vital. In most cases, people who are on ORT are required to visit their health clinic or pharmacy on a...
Evofem Biosciences via PRNewswire, May 22nd 2020 Evofem Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. Phexxi is the first non-hormonal, on-demand...
Hepatitis Australia, 3 April 2020 Hepatitis Australia warmly welcomes recent changes to the Pharmaceutical Benefits Scheme (PBS) allowing authorised Nurse Practitioners to prescribe hepatitis B and hepatitis C medicines under the Highly Specialised Drugs (s100) Program. Both hepatitis B and hepatitis C are under-treated and without improvement in a range of areas Australia risks falling short of...